Reviewer's report

Title: Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants

Version: 3 Date: 2 May 2006

Reviewer: Timothy Pruett

Reviewer's report:

General: needs some clean up of typos. P.5/6 Basiliximab is a Novartis product, Dacluzimab is made by Roche.

-----------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-----------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

-----------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore) The authors should have attempted to assess why some patients developed IAI and others didn't. The variables shown in Table 1 did not appear to correlate with infection. How about graft pancreatitis, duration of hospitalization of the donor, prior antibiotics of either donor or recipient?

Do the authors think that patients with sepsis are more prone to chronic graft loss, as suggested in Fig 2? Do yeast really not play a significant role in IAI infections in their populations (Table 3)? If so, it would be helpful.

What next?: Accept after discretionary revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I declare that I have no competing interests